The Bacteriology of Hidradenitis suppurativa

Jemec, Gregor B. E.; Faber, Mette Tuxen; Gutschik, E; Wendelboe, Peter

doi:10.1159/000246246

Cited by 145 publications

(111 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cultures of HS lesions are often sterile or show common skin flora [3,25,26]. Most commonly found bacteria are coagulase-negative staphylococci (CoNS), Staphylococcus aureus, and strains of the intestinal flora such as Proteus mirabilis, Enterococcus faecalis, or Escherichia coli [26][27][28][29][30][31].…”

Section: Systemic Antibioticsmentioning

confidence: 99%

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Deckers

Prens

2015

Drugs

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent inflammatory nodules mostly located in the armpits and groin. Over the years multiple treatments for HS have been proposed; however, to date a cure is still lacking. In this update we provide an overview of most drug treatments reported on for HS, where possible with their mode of action and side effects. In mild cases, clindamycin lotion or resorcinol cream have proven effective. Tetracyclines are a first-line systemic option in more widespread or severe cases, followed by the combination of clindamycin and rifampicin. However, the recurrence rate is high after discontinuation of clindamycin plus rifampicin combination therapy. Long-term treatment with retinoids, especially acitretin is feasible, although teratogenicity has to be taken into account in females of reproductive age. Multiple antiinflammatory drugs have been suggested for HS, such as dapsone, fumarates or cyclosporine. However, their effectiveness in HS is based on small case series with varying results. If most common treatments have failed, biologics (e.g., infliximab or adalimumab) are the next step. Although not addressed in this review, surgical interventions are often needed to achieve remission. Key PointsHidradenitis suppurativa (HS) is a chronic inflammatory skin disease without a cure.Antibiotics (topical or oral) are often the first treatment option for HS.In cases of more extensive or therapy-resistant HS, biologicals (e.g., infliximab or adalimumab) are a good therapeutic option.

show abstract

Section: Systemic Antibioticsmentioning

confidence: 99%

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Deckers

Prens

2015

Drugs

View full text Add to dashboard Cite

show abstract

“…Bacteria were found in only 50% of all active lesions. Staphylococcus aureus may play a temporary role in the early phase of the disease [28]. The prevalence is about 4% in the general population and women are more frequently affected [29].…”

Section: Infections and Dermatoses Of Appendagesmentioning

confidence: 99%

Dermatoses of the Male Genital Area

Eichmann¹

2005

Dermatology

View full text Add to dashboard Cite

This is an overview of dermatoses which are predominantly seen in the genital area. Five large groups of dermatoses can be distinguished: inflammatory dermatoses without any causative organism, infections and dermatoses originating from cutaneous appendages, precancerous lesions, pigmented lesions and genital pruritus. The etiology, causative factors, clinical features and newer treatment options are considered. Because of local environmental factors, genital dermatoses often present in a different way than in other localizations.

show abstract

“…A large variety of micro-organisms has been isolated from the lesions; the most frequently isolated pathogens are Staphylococcus aureus , Gram-negative rods [4,5,6] and anaerobic bacteria [5, 7]. Unfortunately the clinical significance of superficial and even deep bacterial sampling is very low in the clinical setting [8].…”

Section: Introductionmentioning

confidence: 99%

Combination Therapy with Clindamycin and Rifampicin for Hidradenitis Suppurativa: A Series of 116 Consecutive Patients

Géner¹,

Canouï‐Poitrine²,

Revuz³

et al. 2009

Dermatology

231

175

View full text Add to dashboard Cite

Background: Antibiotics are frequently used to treat hidradenitis suppurativa (HS); however, few data on their efficacy are available. Objective: To evaluate the efficacy of a combination of systemic clindamycin (300 mg twice daily) and rifampicin (600 mg daily) in the treatment of patients with severe HS. Methods: Patients (n = 116) who received this combination were studied retrospectively. The main outcome measure was the severity of the disease, assessed by the Sartorius score, before and after 10 weeks of treatment. Results: The Sartorius score dramatically improved at the end of treatment (median = 29, interquartile range = 14.5, vs. median = 14.5, interquartile range = 11; p < 0.001), as did other parameters of severity as well as the quality of life score. Eight patients (6.9%) stopped the treatment because of side effects. Conclusion: The combination of clindamycin and rifampicin is effective in the treatment of severe HS.

show abstract

The Bacteriology of Hidradenitis suppurativa

Cited by 145 publications

References 0 publications

An Update on Medical Treatment Options for Hidradenitis Suppurativa

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Dermatoses of the Male Genital Area

Combination Therapy with Clindamycin and Rifampicin for Hidradenitis Suppurativa: A Series of 116 Consecutive Patients

Contact Info

Product

Resources

About